NantKwest Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.54 (-5.30 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.20 million shs
Average Volume1.57 million shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NantKwest logo

About NantKwest

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.24 out of 5 stars

Medical Sector

1146th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

170th out of 193 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NantKwest (NASDAQ:NK) Frequently Asked Questions

What stocks does MarketBeat like better than NantKwest?

Wall Street analysts have given NantKwest a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NantKwest wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) posted its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. NantKwest had a negative net margin of 76,658.58% and a negative trailing twelve-month return on equity of 56.06%.
View NantKwest's earnings history

Who are NantKwest's key executives?

NantKwest's management team includes the following people:
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 56, Pay $454.44k)
  • Ms. Sonja Nelson, Chief Financial Officer (Age 48, Pay $442.69k)
  • Mr. Richard Gerald Adcock, Chief Exec. Officer (Age 52)
  • Mr. Steven Yang J.D., VP, Gen. Counsel & Corp. Sec.
  • Dr. Jerel A. Banks Ph.D., M.D., Sr. VP Mergers and Acquisitions (Age 46)
  • Mr. Leonard S. Sender, Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
  • Dr. Hans Georg Klingemann, VP of R&D (Age 71)

What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?

14 employees have rated NantKwest CEO Dr. Patrick Soon-Shiong on Dr. Patrick Soon-Shiong has an approval rating of 55% among NantKwest's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NantKwest's key competitors?

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).

When did NantKwest IPO?

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $9.64.

How much money does NantKwest make?

NantKwest has a market capitalization of $1.05 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does NantKwest have?

NantKwest employs 160 workers across the globe.

What is NantKwest's official website?

The official website for NantKwest is

Where are NantKwest's headquarters?

NantKwest is headquartered at 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected].

This page was last updated on 9/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.